Loading
Tryptophan and Brain Disorders / Immune Cells in Cancer · Journal article
Molecular Psychiatry · July 15, 2026
Encouraging direction, but not yet definitive.
This preclinical study identifies arachidonic acid dysregulation as a mechanistic link between high-fat diet and depression-like behavior in mice, and demonstrates that aspirin reverses these behavioral deficits by suppressing microglial activation and pro-inflammatory lipid metabolites. The work establishes a plausible biological framework but requires human clinical validation before translational claims can be supported.
Preclinical mechanistic study integrating in vivo behavioral models, multi-omics, targeted lipidomics, and in vitro neuron-microglia co-culture assays.. Male mice exposed to chronic high-fat diet; cultured neurons and microglia derived from mice.. Intervention: High-fat diet exposure (≥10 weeks); arachidonic acid supplementation; aspirin treatment as COX-1/COX-2 inhibitor.. Compared with: Standard diet controls; vehicle-treated mice; untreated co-cultures..
Prolonged (≥10 weeks) high-fat diet exposure induced depressive-like behaviors in male mice, phenocopying chronic stress models. Arachidonic acid supplementation alone was sufficient to recapitulate depressive-like behaviors in vivo and directly induce pro-inflammatory microglial activation in neuron-microglia co-cultures. Aspirin treatment effectively reversed high-fat diet-induced behavioral deficits through dual inhibition of microglial activation and suppression of pro-inflammatory ω-6-derived prostanoid biosynthesis, including arachidonic acid and 12-HETE.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
While the mechanistic insights are rigorous and the aspirin intervention shows efficacy in mice, direct application to human depression treatment cannot be inferred from this preclinical work. The findings support further investigation of COX inhibition and polyunsaturated fatty acid metabolism in human depression but should not yet guide clinical practice.
A rigorous preclinical study with multi-omics integration and mechanistic depth, but limited to male mice with surrogate behavioral endpoints; translational relevance to human depression remains unestablished.
As stated by the source record.
Quoted from the source exactly as published.
While the mechanistic insights are rigorous and the aspirin intervention shows efficacy in mice, direct application to human depression treatment cannot be inferred from this preclinical work. The findings support further investigation of COX inhibition and polyunsaturated fatty acid metabolism in human depression but should not yet guide clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
While Western dietary patterns are increasingly linked to neuropsychiatric disorders, the causal mechanisms by which chronic high-fat diet (HFD) contributes to depression remain elusive. Here, we demonstrate that prolonged ( ≥ 10 weeks) HFD exposure in mice robustly induces depressive-like behaviors, phenocopying chronic stress models. Integrating multi-omics and targeted lipidomics, we reveal that HFD-induced behavioral deficits are underpinned by gut microbiota dysbiosis and a profound disruption of polyunsaturated fatty acid (PUFA) homeostasis. This disruption is characterized by a surge in pro-inflammatory ω-6 metabolites, particularly arachidonic acid (AA), alongside a concomitant reduction in anti-inflammatory ω-3 metabolites. These lipid perturbations strongly correlate with marked microglial activation and elevated pro-inflammatory cytokine levels (IL-6, TNF-α, CCL2) in the prefrontal cortex and hippocampus. Functionally, AA supplementation alone was sufficient to recapitulate depressive-like behaviors in vivo and, through neuron-microglia co-culture assays, directly induce pro-inflammatory microglial activation, NF-κB pathway upregulation, and subsequent synaptic impairment in vitro. Critically, therapeutic intervention with aspirin, a dual COX-1/COX-2 inhibitor, effectively reversed HFD-induced behavioral deficits. This protection was mediated by a dual mechanism: directly inhibiting microglial hyperactivation and normalizing the neuroinflammatory milieu by suppressing the biosynthesis of pro-inflammatory ω-6-derived prostanoids, including AA and 12-HETE. Collectively, our findings identify AA as a critical etiological link between HFD and neuroinflammation, establishing a mechanistic framework for "metabolic depression." The profound therapeutic efficacy of aspirin validates the AA metabolic pathway, specifically COX-1/COX-2, as a promising and targetable node for intervention, offering translational insights for the burgeoning field of nutritional psychiatry.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.